[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368893-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368893-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","towards-a-transcriptomic-biomarker-for-the-classification-of-melanocytic-neoplasms","Towards a transcriptomic biomarker for the classification of melanocytic neoplasms","","Histopathologic diagnosis of thin, invasive cutaneous melanoma remains substantially inaccurate, motivating development of a transcriptomic biomarker to separate benign from malignant melanocytic neoplasms. A targeted RNA-sequencing dataset (TempO-Seq) was generated for benign nevi and cutaneous melanoma, with immune-related pathway enrichment observed among differentially expressed genes. A biomarker was trained across datasets including progressing nevi, showing intermediate clustering by principal component analysis; ordinal regularized regression selected a predictive gene set with high model stability and strong classification performance validated by independent regression and external microarray datasets.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/towards-a-transcriptomic-biomarker-for-the-classification-of-melanocytic-neoplasms/368893/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/towards-a-transcriptomic-biomarker-for-the-classification-of-melanocytic-neoplasms/368893.png","ImageObject",300,407,{"name":42,"@type":43},"Blitz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why was a transcriptomic biomarker needed for melanocytic neoplasms?","Question",{"text":63,"@type":64},"Histopathologic diagnosis of thin, invasive cutaneous melanoma is only about 34–62% accurate. This limited performance motivated developing a molecular classifier based on gene expression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What dataset was generated to support biomarker development?",{"text":68,"@type":64},"The study generated a targeted RNA-sequencing dataset (TempO-Seq) including benign nevi (n=50) and cutaneous melanoma (n=51) with Breslow depth ≤ 1.0 mm.",{"name":70,"@type":61,"acceptedAnswer":71},"How was the biomarker trained and evaluated?",{"text":72,"@type":64},"The biomarker was trained across datasets including progression nevi, followed by principal component analysis and ordinal regularized regression. Selected genes were consistently chosen across 1000 bootstrap-based models with predictive accuracy at least 0.90, and performance was further supported by linear regression and publicly available microarray datasets.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368893,1791143958,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","OPEN ACCESS  \nCitation: Borden ES, Hastings CT, Prakash N, Kuo T, Tapia E, Yozwiak M, et al. (2025) Towards a transcriptomic biomarker for the classification of melanocytic neoplasms. PLoS Genet 21(10): e1011869. [https://doi](https://doi). org/10.1371/journal.pgen.1011869  \nEditor: Shuguo Sun, Huazhong University of Science and Technology Tongji Medical College, CHINA  \nReceived: February 9, 2025  \nAccepted: September 3, 2025  \nPublished: October 3, 2025  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pgen.1011869  \nCopyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful  \nRESEARCH ARTICLE  \nTowards a transcriptomic biomarker for the classification of melanocytic neoplasms  \nElizabeth S. Borden1,2, Colin T. Hastings1, Nithish Prakash1, Tyler Kuo1, Edgar Tapia3, Michael Yozwiak3, Paul Sagerman4,5, Danielle Vargas de Stefano6, Kenneth H. Buetow7,8, Melissa A. Wilson7,8,9, Clara Curiel-Lewandrowski3,4, Hsiao-Hui Sherry Chow3,4, Bonnie J. LaFleur10,11, Karen Taraszka Hastings1,2,3*  \n1 Department of Dermatology, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, United States of America, 2 Phoenix Veterans Affairs Health Care System, Phoenix, Arizona, United States of America, 3 University of Arizona Cancer Center, University of Arizona, Tucson, Arizona, United States of America, 4 Department of Medicine, University of Arizona College of Medicine Tucson, Tucson, Arizona, United States of America, 5 Sagis Diagnostics, Houston, Texas, United States of America,  \n6 Department of Pathology and Laboratory Medicine, Phoenix Children’s Hospital, Phoenix, Arizona, United States of America, 7 School of Life Sciences, Arizona State University, Tempe, Arizona, United States of America, 8 Center for Evolution and Medicine, Arizona State University, Tempe, Arizona, United States of America, 9 Comparative Genomics and Reproductive Health Section, Center for Genomicsand Data Science Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America, 10 BIO5 Institute, University of Arizona, Tucson, Arizona, United States of America, 11 R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona, United States of America  \n* [khasting@arizona.edu](khasting@arizona.edu)  \nAbstract  \nHistopathologic diagnosis of thin, invasive cutaneous melanoma (CM) is only 34–62% accurate. Therefore, we sought to develop a transcriptomic biomarker to distinguish benign from malignant melanocytic neoplasms. We generated a targeted RNA-Sequencing dataset (TempO-Seq) of benign nevi (BN; n = 50) and CM (Breslow depth ≤ 1.0 mm; n = 51) and demonstrated enrichment of immune-related pathways among the 450 differentially expressed genes. Next, we trained a putative transcriptomic biomarker in two datasets, including BN and CM, and one dataset with CM in association with a nevus, macrodissected into CM and nevus regions. We refer to the nevus portion of CM in association with a nevus as progressing nevi (PN), since these nevi progressed to CM. Principal component analysis showed that PN samples clustered in a component intermediate to BN and CM. Ordinal regularized regression selected PYGL, AP000845. 1, PHYHIP, WSCD1, FBXO7, TRPM1, SLC4A4, NALCN, FRMD4B, HHATL, COL1A1, CRYM, EPOP, RGS1, KRT6C, IGHG1, CNTN1, MMP11, GZMM, AP001880. 1, TTYH3, TMEM132A, and PRAME; these genes were consistently selected in 1000 models using data from bootstrap resamples and had a single model predictive accuracy of at least 0.90 (area under the receiver operator characteristi","cbCaijfpwtQdR9qW","https://ap.wps.com/l/cbCaijfpwtQdR9qW","pdf",2189429,22,"English","# Abstract\n## Transcriptomic biomarker development and rationale\n## TempO-Seq dataset and differential expression\n## Biomarker training, progression nevi, and model selection\n## Validation using external datasets","[{\"question\":\"Why was a transcriptomic biomarker needed for melanocytic neoplasms?\",\"answer\":\"Histopathologic diagnosis of thin, invasive cutaneous melanoma is only about 34–62% accurate. This limited performance motivated developing a molecular classifier based on gene expression.\"},{\"question\":\"What dataset was generated to support biomarker development?\",\"answer\":\"The study generated a targeted RNA-sequencing dataset (TempO-Seq) including benign nevi (n=50) and cutaneous melanoma (n=51) with Breslow depth ≤ 1.0 mm.\"},{\"question\":\"How was the biomarker trained and evaluated?\",\"answer\":\"The biomarker was trained across datasets including progression nevi, followed by principal component analysis and ordinal regularized regression. Selected genes were consistently chosen across 1000 bootstrap-based models with predictive accuracy at least 0.90, and performance was further supported by linear regression and publicly available microarray datasets.\"}]","Towards a transcriptomic biomarker for the classification of melanocytic neoplasms | PDF",1790179118,55,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ff5d405b778f53516cc92010aef9f02.webp",983,1272,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36af7183afa8b7a1b7654f5fd8c29e3a.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e17eca5113d94ef429fafb58e1d63252.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/339093be14d5650847474bb2eebe7ec6.webp",980,1268]